- Home
- BNZI vs IMNN Comparison
BNZI vs IMNN Comparison
Compare BNZI & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNZI
- IMNN
- Stock Information
- Founded
- BNZI 2016
- IMNN 1982
- Country
- BNZI United States
- IMNN United States
- Employees
- BNZI N/A
- IMNN N/A
- Industry
- BNZI
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- BNZI
- IMNN Health Care
- Exchange
- BNZI Nasdaq
- IMNN Nasdaq
- Market Cap
- BNZI 11.5M
- IMNN 12.1M
- IPO Year
- BNZI N/A
- IMNN 1985
- Fundamental
- Price
- BNZI $3.87
- IMNN $7.00
- Analyst Decision
- BNZI Strong Buy
- IMNN Buy
- Analyst Count
- BNZI 1
- IMNN 2
- Target Price
- BNZI $240.00
- IMNN $14.00
- AVG Volume (30 Days)
- BNZI 288.0K
- IMNN 4.1M
- Earning Date
- BNZI 08-13-2025
- IMNN 08-13-2025
- Dividend Yield
- BNZI N/A
- IMNN N/A
- EPS Growth
- BNZI N/A
- IMNN N/A
- EPS
- BNZI N/A
- IMNN N/A
- Revenue
- BNZI $6,827,490.00
- IMNN N/A
- Revenue This Year
- BNZI $337.60
- IMNN N/A
- Revenue Next Year
- BNZI $91.81
- IMNN N/A
- P/E Ratio
- BNZI N/A
- IMNN N/A
- Revenue Growth
- BNZI 52.95
- IMNN N/A
- 52 Week Low
- BNZI $3.51
- IMNN $0.37
- 52 Week High
- BNZI $112.00
- IMNN $7.66
- Technical
- Relative Strength Index (RSI)
- BNZI 31.92
- IMNN 35.49
- Support Level
- BNZI $3.79
- IMNN $7.46
- Resistance Level
- BNZI $4.44
- IMNN $9.35
- Average True Range (ATR)
- BNZI 0.46
- IMNN 1.23
- MACD
- BNZI 0.11
- IMNN 0.08
- Stochastic Oscillator
- BNZI 15.45
- IMNN 9.00
About BNZI Banzai International Inc.
Banzai International Inc is a marketing technology (MarTech) company that produces data-driven marketing and sales solutions for businesses of all sizes. Its mission is to help its customers accomplish their mission by enabling marketing, sales and customer engagement outcomes. The company has two reportable operating segments, Banzai Operating and OpenReel. The company's segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions for business of all size. it derives maximum revenue from Banzai Operating segment. Geographically, it operates in Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).